- Conditions
- Cerebral Vein Thrombosis, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Pulmonary Embolism, Splanchnic Vein Thrombosis
- Interventions
- Apixaban
- Drug
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 32
- States / cities
- Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 27 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 773
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Metoprolol succinate, Placebo
- Drug · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 40 Years to 84 Years
- Enrollment
- 532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Fresno, California • Los Angeles, California + 21 more
- Conditions
- Hypertension
- Interventions
- SMI, HEI, UC
- Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 21 Years and older
- Enrollment
- 533 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Preeclampsia Postpartum
- Interventions
- Remote Patient Monitoring
- Device
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Coronary Artery Disease, Acute Myocardial Infarction
- Interventions
- Enoxaparin
- Drug
- Lead sponsor
- Corewell Health East
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Royal Oak, Michigan • Syracuse, New York + 3 more
- Conditions
- Pre-Eclampsia, Hypertension in Pregnancy, Obesity
- Interventions
- Aspirin 81 mg, Aspirin 162 mg
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Venous Thromboembolism, Traumatic Brain Injury
- Interventions
- enoxaparin, placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Tyler, Texas
- Conditions
- Diabetes, Cardiovascular Risk Factor
- Interventions
- Current Intervention, Delayed Intervention
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Antiphospholipid Syndrome, Thrombosis
- Interventions
- Apixaban, Warfarin
- Drug
- Lead sponsor
- Scott C. Woller, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Murray, Utah
- Conditions
- Fall, Fall Injury, Peripheral Artery Disease, Peripheral Arterial Disease
- Interventions
- Adapted Otago Exercise Program (OEP)
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Atrial Fibrillation
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12,507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Coronary Artery Disease, Peripheral Arterial Disease, Hyperlipidemia, Hypertension, Diabetes, Prediabetes, Obesity
- Interventions
- Prevention Consult, Consult & Behavioral Intervention
- Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 21 Years to 99 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hypertension
- Interventions
- Community-Based Multidisciplinary Hypertension Management Program
- Behavioral
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Coronary Heart Disease
- Interventions
- Lifestyle Physical Activity Intervention, Information / Attention Comparison
- Behavioral
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 60 Years and older · Female only
- Enrollment
- 121 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Deep Venous Thrombosis
- Interventions
- Low-Molecular-Weight Heparin
- Drug
- Lead sponsor
- University of Tennessee
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Chattanooga, Tennessee
- Conditions
- Cancer
- Interventions
- acyclovir, acyclovir sodium, valacyclovir
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 6
- States / cities
- Duarte, California • Stanford, California • Omaha, Nebraska + 3 more
- Conditions
- Venous Insufficiency of Leg, Venous Reflux, Varicose Veins, Lower Extremity Edema Chronic
- Interventions
- Vasculera, Placebo
- Other
- Lead sponsor
- Corewell Health West
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- CSL312
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Litchfield Park, Arizona • Scottsdale, Arizona • Orange, California + 4 more
- Conditions
- Age Related Cognitive Decline, Alzheimer's Disease, Vascular Dementia, Endothelial Dysfunction, Executive Dysfunction
- Interventions
- Omega 3 PUFA, Placebo
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Post Operative Atrial Fibrillation, Atrial Fibrillation, Postoperative
- Interventions
- Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System
- Device
- Lead sponsor
- AtriCure, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 960 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 24
- States / cities
- Jonesboro, Arkansas • San Diego, California • Clearwater, Florida + 19 more
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Graft Versus Host Disease, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Waldenström Macroglobulinemia
- Interventions
- rituximab, mycophenolate mofetil, tacrolimus, anti-thymocyte globulin, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis, graft versus host disease prophylaxis/therapy, cyclophosphamide, fludarabine phosphate, busulfan, total-body irradiation, graft-versus-tumor induction therapy, immunosuppressive therapy
- Drug · Procedure · Other + 2 more
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Tachycardia, Ventricular, Implantable Cardioverter Defibrillator (ICD), Fibrillation, Ventricular, Syncope
- Interventions
- Implanted Device
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 28 more
- Conditions
- Venous Thromboembolism
- Interventions
- Rivaroxaban (BAY59-7939), Enoxaparin
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Northport, Alabama • Phoenix, Arizona + 10 more
- Conditions
- Medication Adherence
- Interventions
- 5 Behavioral Change Techniques
- Behavioral
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York